Vendor, Malvern, PA
Venatorx Pharmaceuticals Inc.
UEI MBBKNBU5DCC6, CAGE 61SY9
6 awards and $40,477,464 obligated between January 19, 2024 and August 4, 2026, 100% under full and open competition, against 5.5 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $31,255,006 |
| National Institutes of Health | $9,682,676 |
| Defense Threat Reduction Agency | -$460,217 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $31,255,006 |
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $9,663,738 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$441,280 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 6 |
| Definitive Contract | 6 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00050Definitive Contract, January 31, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Update Article G.7 Indirect Cost RateNAICS 541714, PSC AN13 | $24,870,405 |
| 75N93020C00016Definitive Contract, July 1, 2024, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | Non Beta-Lactam Inhibitors of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.NAICS 541715, PSC AN12 | $9,663,738 |
| 75A50119C00007Definitive Contract, January 19, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Correct the Period of Performance for Clin0007 to Align with Ipp.NAICS 541714, PSC AN13 | $6,384,601 |
| HHSN272201600029CDefinitive Contract, June 28, 2024, Full and Open Competition, 13 offers | National Institutes of Health NiaidNational Institutes of Health | The Purpose of This Contract Is the Development of a Novel Orally Bioavailable Beta-Lactamase Inhibitor Through Delivery to the Government ONAICS 541711, PSC AN12 | $18,938 |
| 75A50122C00080Definitive Contract, January 24, 2024, Full and Open Competition, 3 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Update Article G.12. Indirect Cost RateNAICS 541714, PSC 6505 | $0 |
| HDTRA117C0070Definitive Contract, February 17, 2026, Full and Open Competition, 3 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | New PBP Inhibitors Impervious to Beta-LactamasesNAICS 541711, PSC AD92 | -$460,217 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN12 Health R&D Services; Health Care Services; Applied Research6505 Drugs and BiologicalsAD92
- Transactions
- 31 across 6 awards